CannaMED Enterprises 10-Q 15 May 18 2018 Q1 Quarterly report Financial data

Document And Entity Information

Document And Entity Information - shares	3 Months Ended
	Mar. 31, 2018	May 15, 2018
Document Information [Line Items]
Entity Registrant Name	CannaMED Enterprises, Inc.
Entity Central Index Key	1,623,016
Current Fiscal Year End Date	--12-31
Entity Filer Category	Smaller Reporting Company
Entity Current Reporting Status	Yes
Entity Voluntary Filers	No
Entity Well-known Seasoned Issuer	No
Entity Common Stock, Shares Outstanding (in shares)		3,500,000
Document Type	10-Q
Document Period End Date	Mar. 31, 2018
Document Fiscal Year Focus	2,018
Document Fiscal Period Focus	Q1
Amendment Flag	false

Condensed Balance Sheets (Curre

Condensed Balance Sheets (Current Period Unaudited) - USD ($)	Mar. 31, 2018	Dec. 31, 2017
ASSETS
Prepaid expenses	$ 1,650	$ 2,500
TOTAL ASSETS	1,650	2,500
LIABILITIES AND STOCKHOLDERS’ EQUITY
Accounts payable and accrued expenses	7,580	1,080
Related party payable	42,904	40,504
TOTAL LIABILITIES	50,484	41,584
STOCKHOLDERS’ DEFICIT
Preferred stock, $0.0001 par value, 20,000,000 shares authorized, none issued and outstanding as of March 31, 2018 and December 31, 2017, respectively
Common stock, $0.0001 par value, 100,000,000 shares authorized, 3,500,000 issued and outstanding as of March 31, 2018 and December 31, 2017, respectively	350	350
Discount on common stock	(350)	(350)
Additional paid in capital	21,730	21,730
Accumulated deficit	(70,564)	(60,814)
Total Stockholders’ Deficit	(48,834)	(39,084)
TOTAL LIABILITIES AND STOCKHOLDERS’ DEFICIT	$ 1,650	$ 2,500

Condensed Balance Sheets (Curr3

Condensed Balance Sheets (Current Period Unaudited) (Parentheticals) - $ / shares	Mar. 31, 2018	Dec. 31, 2017
Preferred stock, par value (in dollars per share)	$ 0.0001	$ 0.0001
Preferred stock, shares authorized (in shares)	20,000,000	20,000,000
Preferred stock, shares issued (in shares)	0	0
Preferred stock, shares outstanding (in shares)	0	0
Common stock, par value (in dollars per share)	$ 0.0001	$ 0.0001
Common stock, shares authorized (in shares)	100,000,000	100,000,000
Common stock, shares issued (in shares)	3,500,000	3,500,000
Common stock, shares outstanding (in shares)	3,500,000	3,500,000

Condensed Statements of Operati

Condensed Statements of Operations (Unaudited) - USD ($)	3 Months Ended
	Mar. 31, 2018	Mar. 31, 2017
REVENUES
COST OF REVENUES
GROSS PROFIT
Operating expenses	9,750	13,829
TOTAL OPERATING EXPENSES	9,750	13,829
LOSS FROM OPERATIONS	(9,750)	(13,829)
LOSS BEFORE PROVISION FOR INCOME TAXES	(9,750)	(13,829)
Provision for income taxes	0	0
NET LOSS	$ (9,750)	$ (13,829)
NET LOSS PER SHARE OF COMMON STOCK - Basic and diluted (in dollars per share)
WEIGHTED AVERAGE COMMON SHARES OUTSTANDING - Basic and diluted (in shares)	3,500,000	3,500,000

Condensed Statements of Cash Fl

Condensed Statements of Cash Flows (Unaudited) - USD ($)	3 Months Ended
	Mar. 31, 2018	Mar. 31, 2017
OPERATING ACTIVITIES:
Net loss	$ (9,750)	$ (13,829)
Changes in Operating Assets and Liabilities
Prepaid expenses	850
Accrued liability	6,500
Net cash used in operating activities	(2,400)	(13,829)
INVESTING ACTIVITIES:
Net cash used in investing activities
FINANCING ACTIVITIES:
Proceeds from related party payable	2,400	13,829
Net cash provided by financing activities	2,400	13,829
Net increase (decrease) in cash
Cash at beginning of period
Cash at end of period
Supplemental disclosure of cash flow information:
Cash paid for interest
Cash paid for income tax

Note 1 - Basis of Presentation

Note 1 - Basis of Presentation and Organization	3 Months Ended
	Mar. 31, 2018
Notes to Financial Statements
Organization, Consolidation and Presentation of Financial Statements Disclosure and Significant Accounting Policies [Text Block]	NOTE 1 Nature of Operations and Background CannaMED Enterprises, Inc. (“CannaMED” or “the Company”) was incorporated on September 25, 2014 not 1934. 351 368 1986, During the period covered by this report, the Company located such a target and began the process to effect a change in control. On August 24, 2015, 1. The officers and directors of Redwood Valley, James Cassidy and James McKillop, entered into a Share Purchase Agreement (the “SPA”) pursuant to which they entered into an agreement to sell an aggregate of 19,500,000 $75,000. 98% 7% 2. The Company redeemed and cancelled an aggregate of 19,500,000 20,000,000 $.0001 3. Mikhail Artamonov was named President, Secretary and Chief Financial Officer of the Company. He now serves as the Chief Executive Officer, Secretary, Chief Financial Officer and Director of the Company. On August 25, 2015, 3,000,000 86% 3,500,000 The Company envisions to initially enter into joint ventures or acquire partial ownership in: ● a laboratory for medical cannabis testing, a pharmacy to perform research; ● a pharmacy to perform research and development of the newest medical cannabis formulations; ● a clinical practice to establish the network dispensaries; ● a packaging company; ● a research facility; and ● real estate to establish the foundation for the growing network Basis of Presentation The accompanying financial statements have been prepared in conformity with accounting principles generally accepted in the United States of America (“GAAP”). Intercompany accounts and transactions have been eliminated. Use of Estimates The preparation of financial statements in conformity with GAAP requires management to make estimates and assumptions that may Income Taxes CannaMED accounts for income taxes in accordance with ASC 740, 740” not ASC 740 740 not not Cash and Cash Equivalents Cash and cash equivalents includes all highly liquid instruments with an original maturity of three March 31, 2018. not March 31, 2018 December 31, 2017. Concentration of Risk Financial instruments that potentially subject the Company to concentrations of credit risk consist principally of cash. The Company places its cash with high quality banking institutions. The Company did not March 31, 2018 December 31, 2017. Fair Value of Financial Instruments The Company adopted ASC 820, 820 820 three three ● Level 1 ● Level 2 ● Level 3 The carrying value of cash, accounts payables and accrued expenses approximates their fair values due to their short-term maturities at March 31, 2018 December 31, 2017. Revenue Recognition The Company will recognize revenue in accordance with ASC 605, 605 four 1 2 3 4 Net Loss Per Share Basic net loss per share is computed by dividing the net loss applicable to common shareholders by the weighted average number of shares of common stock outstanding for the period. Diluted loss per share is computed by dividing the loss applicable to common shareholders by the weighted average number of common shares outstanding plus the number of additional common shares that would have been outstanding if all dilutive potential common shares had been issued, using the treasury stock method. Due to the Company’s losses in the periods presented, the Company currently has no

Note 2 - Going Concern

Note 2 - Going Concern	3 Months Ended
	Mar. 31, 2018
Notes to Financial Statements
Going Concern [Text Block]	NOTE 2 CannaMED has not March 31, 2018, $48,834 $70,564. may The accompanying financial statements have been prepared assuming that the Company will continue as a going concern; however, the above condition raises substantial doubt about the Company's ability to do so. The financial statements do not may In order to maintain its current level of operations, the Company will require additional working capital from either cash flow from operations, loans from officers, or from the sale of its equity. However, the Company currently has no third

Note 3 - Recent Accounting Pron

Note 3 - Recent Accounting Pronouncements	3 Months Ended
	Mar. 31, 2018
Notes to Financial Statements
New Accounting Pronouncements and Changes in Accounting Principles [Text Block]	NOTE 3 In March 2016, December 15, 2016, In March 2016, April 2016, December 15, 2017, In February 2016, December 15, 2018, Beginning January 1, 2018, 606, Revenue from Contracts with Customers 606, 606 January 1, 2018, 606 no no no no Other Pronouncements not not may

Note 4 - Stockholders' Deficit

Note 4 - Stockholders' Deficit	3 Months Ended
	Mar. 31, 2018
Notes to Financial Statements
Stockholders' Equity Note Disclosure [Text Block]	NOTE 4 Preferred Stock - 20,000,000 $0.0001 no March 31, 2018 December 31, 2017. Common Stock - $0.0001 100,000,000 3,500,000 March 31, 2018 December 31, 2017. The current ownership structure is as follows: Common Shares Percent Mikhail Artamonov 3,000,000 86 % James McKillop 250,000 7 % James Cassidy 250,000 7 % 3,500,000 100 %

Note 5 - Income Tax

Note 5 - Income Tax	3 Months Ended
	Mar. 31, 2018
Notes to Financial Statements
Income Tax Disclosure [Text Block]	NOTE 5 The Company has not not not. not.

Significant Accounting Policies

Significant Accounting Policies (Policies)	3 Months Ended
	Mar. 31, 2018
Accounting Policies [Abstract]
Basis of Accounting, Policy [Policy Text Block]	Basis of Presentation The accompanying financial statements have been prepared in conformity with accounting principles generally accepted in the United States of America (“GAAP”). Intercompany accounts and transactions have been eliminated.
Use of Estimates, Policy [Policy Text Block]	Use of Estimates The preparation of financial statements in conformity with GAAP requires management to make estimates and assumptions that may
Income Tax, Policy [Policy Text Block]	Income Taxes CannaMED accounts for income taxes in accordance with ASC 740, 740” not ASC 740 740 not not
Cash and Cash Equivalents, Policy [Policy Text Block]	Cash and Cash Equivalents Cash and cash equivalents includes all highly liquid instruments with an original maturity of three March 31, 2018. not March 31, 2018 December 31, 2017.
Concentration Risk, Credit Risk, Policy [Policy Text Block]	Concentration of Risk Financial instruments that potentially subject the Company to concentrations of credit risk consist principally of cash. The Company places its cash with high quality banking institutions. The Company did not March 31, 2018 December 31, 2017.
Fair Value of Financial Instruments, Policy [Policy Text Block]	Fair Value of Financial Instruments The Company adopted ASC 820, 820 820 three three ● Level 1 ● Level 2 ● Level 3 The carrying value of cash, accounts payables and accrued expenses approximates their fair values due to their short-term maturities at March 31, 2018 December 31, 2017.
Revenue Recognition, Policy [Policy Text Block]	Revenue Recognition The Company will recognize revenue in accordance with ASC 605, 605 four 1 2 3 4
Earnings Per Share, Policy [Policy Text Block]	Net Loss Per Share Basic net loss per share is computed by dividing the net loss applicable to common shareholders by the weighted average number of shares of common stock outstanding for the period. Diluted loss per share is computed by dividing the loss applicable to common shareholders by the weighted average number of common shares outstanding plus the number of additional common shares that would have been outstanding if all dilutive potential common shares had been issued, using the treasury stock method. Due to the Company’s losses in the periods presented, the Company currently has no

Note 4 - Stockholders' Deficit

Note 4 - Stockholders' Deficit (Tables)	3 Months Ended
	Mar. 31, 2018
Notes Tables
Schedule of Other Ownership Interests [Table Text Block]	Common Shares Percent Mikhail Artamonov 3,000,000 86 % James McKillop 250,000 7 % James Cassidy 250,000 7 % 3,500,000 100 %

Note 1 - Basis of Presentatio13

Note 1 - Basis of Presentation and Organization (Details Textual) - USD ($)	Aug. 25, 2015	Aug. 24, 2015	Mar. 31, 2018	Mar. 31, 2017	Dec. 31, 2017
Equity Method Investment, Ownership Percentage			100.00%
Common Stock, Shares, Outstanding, Ending Balance			3,500,000		3,500,000
Cash Equivalents, at Carrying Value, Total			$ 0		$ 0
Cash, Uninsured Amount			$ 0		$ 0
Weighted Average Number Diluted Shares Outstanding Adjustment, Total			0	0
Mikhail Artamonov [Member]
Stock Issued During Period, Shares, New Issues	3,000,000	19,500,000
Stock Issued During Period, Value, New Issues		$ 75,000
Share-based Compensation Arrangement by Share-based Payment Award, Percentage of Outstanding Stock Maximum		98.00%
Equity Method Investment, Ownership Percentage	86.00%	7.00%
Stock Redeemed or Called During Period, Shares		19,500,000
Common Stock, Shares, Outstanding, Ending Balance	3,500,000	20,000,000
Sale of Stock, Price Per Share		$ 0.0001

Note 2 - Going Concern (Details

Note 2 - Going Concern (Details Textual) - USD ($)	Mar. 31, 2018	Dec. 31, 2017
Working Capital	$ (48,834)
Retained Earnings (Accumulated Deficit), Ending Balance	$ (70,564)	$ (60,814)

Note 4 - Stockholders' Defici15

Note 4 - Stockholders' Deficit (Details Textual) - $ / shares	Mar. 31, 2018	Dec. 31, 2017
Preferred Stock, Shares Authorized	20,000,000	20,000,000
Preferred Stock, Par or Stated Value Per Share	$ 0.0001	$ 0.0001
Preferred Stock, Shares Issued, Total	0	0
Common Stock, Par or Stated Value Per Share	$ 0.0001	$ 0.0001
Common Stock, Shares Authorized	100,000,000	100,000,000
Common Stock, Shares, Issued, Total	3,500,000	3,500,000
Common Stock, Shares, Outstanding, Ending Balance	3,500,000	3,500,000

Note 4 - Stockholders' Defici16

Note 4 - Stockholders' Deficit - Ownership Structure (Details) - shares	Mar. 31, 2018	Dec. 31, 2017
Common stock, shares issued (in shares)	3,500,000	3,500,000
Percent	100.00%
Mikhail Artamonov [Member]
Common stock, shares issued (in shares)	3,000,000
Percent	86.00%
James Mckillop [Member]
Common stock, shares issued (in shares)	250,000
Percent	7.00%
James Cassidy [Member]
Common stock, shares issued (in shares)	250,000
Percent	7.00%

Note 5 - Income Tax (Details Te

Note 5 - Income Tax (Details Textual) - USD ($)	3 Months Ended
	Mar. 31, 2018	Mar. 31, 2017
Income Tax Expense (Benefit), Total	$ 0	$ 0